Emerging Long-Term Evidence of Biomarker Data, Survival and ALS Clinical Worsening Improvements
Merit Cudkowicz, MD, MSC, Director of the Sean M. Healey & AMG Center for ALS, Chair of Neurology at Mass General, Director and the Julieanne Dorn Professor of Neurology at Harvard Medical School, will present the current data from the CNM-Au8 Clinical Development Platform. Robert Bowser, PhD, is Chief Scientific Officer, the John P. and Betty Van Denburgh Chair for Neuromuscular Disease, and Professor and Chair of the Department of Translational Neuroscience at Barrow Neurological Institute, will present new long-term biomarker data including glutathione and NfL. Benjamin Greenberg, MD, MHS, FAAN, Clene Head of Medical, will share plans for RESTORE-ALS, Global Phase 3 clinical trial, and the regulatory path forward with FDA for CNM-Au8 in ALS.
Moderated by
Jinsy A. Andrews, MD, MSc, FAAN is an Associate Professor of Neurology, in the Division of Neuromuscular Medicine and serves as the Director of Neuromuscular Clinical Trials.
